Avustralya - İngilizce - APVMA (Australian Pesticides and Veterinary Medicines Authority)

intervet australia pty limited - clostridium chauvoei - killed; clostridium novyi type b - killed; clostridium chauvoei - toxoid; clostridium novyi type b - toxoid; clostridium perfringens type d toxoid; clostridium septicum - toxoid; clostridium tetani - toxoid; thiomersal - misc. vaccines or anti sera - clostridium chauvoei - killed vaccine-microbial active 0.0 p; clostridium novyi type b - killed vaccine-microbial active 0.0 p; clostridium chauvoei - toxoid vaccine-toxoid active 0.0 p; clostridium novyi type b - toxoid vaccine-toxoid active 0.0 p; clostridium perfringens type d toxoid vaccine-toxoid active 0.0 p; clostridium septicum - toxoid vaccine-toxoid active 0.0 p; clostridium tetani - toxoid vaccine-toxoid active 0.0 p; thiomersal mercury other 0.15 mg/ml - immunotherapy - cattle | goat | sheep | beef | billy | bos indicus | bos taurus | bovine | buck | buffalo | bull | bullock | calf | capra hircus - black disease | blackleg | enterotoxaemia (pulpy kidney) | malignant oedema | tetanus | clostridium perfringens type d | tetanus vaccination

Avustralya - İngilizce - APVMA (Australian Pesticides and Veterinary Medicines Authority)

adama australia pty limited - chlorpyrifos; hydrocarbon solvent; liquid hydrocarbon - emulsifiable concentrate - chlorpyrifos organophosphorus active 500.0 g/l; hydrocarbon solvent solvent other 520.0 g/l; liquid hydrocarbon solvent other 480.0 g/l - insecticide - agricultural area - general | annual pasture-improved | apple | avocado | banana | barley | broad bean | broccoli | brussels spr - african black beetle | ant | argentine ant | argentine stem weevil | australian plague locust | avocado leafroller | banana scab moth | banana weevil borer | black beetle | blackheaded pasture cockchafer | blue oat or pea mite | bluegreen aphid | brown pasture looper | brown planthopper | cabbage aphid | cabbage cluster caterpillar | cabbage moth | cabbage white butterfly | california red scale | caterpillar | cluster caterpillar | cockroach | common armyworm - mythimna convecta | common mango scale | corn aphid | corn earworm | cotton aphid | cotton flea beetle | cricket | cutworm | cutworm - agrotis spp. | cutworm in young plants | european earwig | false wireworm | false wireworm - celibe spp. | field cricket | funnel ant | grapevine moth | grapevine scale | green peach aphid | green vegetable bug | hairy caterpillar | ivy leafroller | latania scale | lawn armyworm | light brown apple moth | lucerne flea | lucerne leafroller | migratory locust | mole cricket | mole cricket - gryllotalpa spp. | native budwo

Avustralya - İngilizce - APVMA (Australian Pesticides and Veterinary Medicines Authority)

nufarm australia limited - chlorpyrifos; hydrocarbon solvent - emulsifiable concentrate - chlorpyrifos organophosphorus active 500.0 g/l; hydrocarbon solvent solvent other 480.0 g/l - insecticide - building | commercial/industrial premises | domestic and/or public area | log, post and pole | polluted water | stored animal hi - ant | argentine ant | cockroach | flea | giant termite | hide or skin beetle | mosquito | mosquito larva | silverfish | spider | subterranean termite - coptotermes spp. | subterranean termite ex. m. darwiniensis | adult mosquitoes | argentine ant | coptotermes acinaciformis | coptotermes frenchi | coptotermes lacteus | coptotermes spp. | ctenocephalides spp. | dermestes ater | dermestes maculatus | giant northern termite | ground fleas | large cockroach | linepithema humile | ochlerotatus vigilax | pharaoh ant | schedorhinotermes spp. | small cockroach

Avustralya - İngilizce - APVMA (Australian Pesticides and Veterinary Medicines Authority)

nutrien ag solutions limited - chlorpyrifos; liquid hydrocarbon - emulsifiable concentrate - chlorpyrifos organophosphorus active 500.0 g/l; liquid hydrocarbon solvent other 488.0 g/l - insecticide

Avustralya - İngilizce - APVMA (Australian Pesticides and Veterinary Medicines Authority)

nutrien ag solutions limited - atrazine - water dispersible granule - atrazine triazine active 900.0 g/kg - herbicide

Avustralya - İngilizce - APVMA (Australian Pesticides and Veterinary Medicines Authority)

elders rural services australia limited - chlorpyrifos; hydrocarbon liquid - emulsifiable concentrate - chlorpyrifos organophosphorus active 500.0 g/l; hydrocarbon liquid solvent other 520.0 g/l - insecticide

Kanada - İngilizce - Health Canada

janssen inc - itraconazole - capsule - 100mg - itraconazole 100mg - azoles

Avrupa Birliği - İngilizce - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - idarucizumab - hemorrhage - all other therapeutic products - praxbind is a specific reversal agent for dabigatran and is indicated in adult patients treated with pradaxa (dabigatran etexilate) when rapid reversal of its anticoagulant effects is required:for emergency surgery/urgent procedures;in life-threatening or uncontrolled bleeding.

ABD - İngilizce - NLM (National Library of Medicine)

fresenius kabi usa, llc - furosemide (unii: 7lxu5n7zo5) (furosemide - unii:7lxu5n7zo5) - furosemide 10 mg in 1 ml - furosemide injection is indicated in adults and pediatric patients for the treatment of edema associated with heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome. furosemide injection is indicated as adjunctive therapy in acute pulmonary edema. - furosemide injection is contraindicated in patients with anuria. - furosemide injection is contraindicated in patients with a history of hypersensitivity to furosemide. risk summary available data from published observational studies, case reports, and postmarketing reports, from decades of use, have not demonstrated a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes with furosemide use during pregnancy. untreated congestive heart failure and cirrhosis of the liver can lead to adverse outcomes for the mother and the fetus (see clinical considerations) . in animal reproduction studies, furosemide has been shown to cause unexplained maternal deaths and abortions in rabbits when administered orally during organogenesis at 4 times a human i.v. dose of 80 mg based on body surface area (bsa) and oral bioavailability corrections, presumably secondary to volume depletion (see data) . the estimated background risk for major birth defects and miscarriage for the indicated populations is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in the clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. clinical considerations disease-associated maternal and/or embryo/fetal risk pregnant women with congestive heart failure are at increased risk for pre-term birth. stroke volume and heart rate increase during pregnancy, increasing cardiac output, especially during the first trimester. clinical classification of heart disease may worsen with pregnancy and lead to maternal death and/or stillbirth. closely monitor pregnant patients for destabilization of their heart failure. pregnant women with symptomatic cirrhosis generally have poor outcomes including hepatic failure, variceal hemorrhage, pre-term delivery, fetal growth restriction and maternal death. outcomes are worse with coexisting esophageal varices. pregnant women with cirrhosis of the liver should be carefully monitored and managed accordingly. data animal data the effects of furosemide on embryonic and fetal development and on pregnant dams were studied in mice, rats and rabbits. furosemide caused unexplained maternal deaths and abortions in the rabbit at the lowest dose of 25 mg/kg (approximately 4 times a human i.v. dose of 80 mg based on bsa and oral bioavailability corrections). in another study, a dose of 50 mg/kg (approximately 7 times a human i.v. dose of 80 mg based on bsa and oral bioavailability corrections) also caused maternal deaths and abortions when administered to rabbits between days 12 and 17 of gestation. in a third study, none of the pregnant rabbits survived an oral dose of 100 mg/kg. data from the above studies indicate fetal lethality that can precede maternal deaths. the results of the mouse study and one of the three rabbit studies also showed an increased incidence and severity of hydronephrosis (distention of the renal pelvis and, in some cases, of the ureters) in fetuses of treated dams as compared with the incidence of fetuses from the control group. risk summary the presence of furosemide has been reported in human milk. there are no data on the effects on the breastfed infant or the effects on milk production. doses of furosemide associated with clinically significant diuresis may impair milk production. the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for furosemide and any potential adverse effects on the breastfed infant from furosemide or from the underlying maternal condition. published reports indicate that premature infants with post conceptual age (gestational plus postnatal) less than 31 weeks receiving doses exceeding 1 mg/kg/24 hours may develop plasma levels which could be associated with potential toxic effects including ototoxicity [see warnings and precautions (5.3)] . furosemide in the first year of life, especially in patients born pre-term, may precipitate nephrocalcinosis/nephrolithiasis [see warnings and precautions (5.2)] . controlled clinical studies of furosemide did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. other reported clinical experience has not identified differences in responses between the elderly and younger patients. in general, dose selection for the elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy. this drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. because elderly patients are more likely to have decreased renal function, care should be taken in dose selection and it may be useful to monitor renal function [see clinical pharmacology (12.3)] .

ABD - İngilizce - NLM (National Library of Medicine)

fresenius kabi usa, llc - furosemide (unii: 7lxu5n7zo5) (furosemide - unii:7lxu5n7zo5) - furosemide injection is indicated in adults and pediatric patients for the treatment of edema associated with heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome. furosemide injection is indicated as adjunctive therapy in acute pulmonary edema. - furosemide injection is contraindicated in patients with anuria. - furosemide injection is contraindicated in patients with a history of hypersensitivity to furosemide. risk summary available data from published observational studies, case reports, and postmarketing reports, from decades of use, have not demonstrated a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes with furosemide use during pregnancy. untreated congestive heart failure and cirrhosis of the liver can lead to adverse outcomes for the mother and the fetus (see clinical considerations) . in animal reproduction studies, furosemide has been shown to cause unexplained maternal deaths and abortions in rabbits when administered orally during organogenesis at 4 times a human i.v. dose of 80 mg based on body surface area (bsa) and oral bioavailability corrections, presumably secondary to volume depletion (see data) . the estimated background risk for major birth defects and miscarriage for the indicated populations is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in the clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. clinical considerations disease-associated maternal and/or embryo/fetal risk pregnant women with congestive heart failure are at increased risk for pre-term birth. stroke volume and heart rate increase during pregnancy, increasing cardiac output, especially during the first trimester. clinical classification of heart disease may worsen with pregnancy and lead to maternal death and/or stillbirth. closely monitor pregnant patients for destabilization of their heart failure. pregnant women with symptomatic cirrhosis generally have poor outcomes including hepatic failure, variceal hemorrhage, pre-term delivery, fetal growth restriction and maternal death. outcomes are worse with coexisting esophageal varices. pregnant women with cirrhosis of the liver should be carefully monitored and managed accordingly. data animal data the effects of furosemide on embryonic and fetal development and on pregnant dams were studied in mice, rats and rabbits. furosemide caused unexplained maternal deaths and abortions in the rabbit at the lowest dose of 25 mg/kg (approximately 4 times a human i.v. dose of 80 mg based on bsa and oral bioavailability corrections). in another study, a dose of 50 mg/kg (approximately 7 times a human i.v. dose of 80 mg based on bsa and oral bioavailability corrections) also caused maternal deaths and abortions when administered to rabbits between days 12 and 17 of gestation. in a third study, none of the pregnant rabbits survived an oral dose of 100 mg/kg. data from the above studies indicate fetal lethality that can precede maternal deaths. the results of the mouse study and one of the three rabbit studies also showed an increased incidence and severity of hydronephrosis (distention of the renal pelvis and, in some cases, of the ureters) in fetuses of treated dams as compared with the incidence of fetuses from the control group. risk summary the presence of furosemide has been reported in human milk. there are no data on the effects on the breastfed infant or the effects on milk production. doses of furosemide associated with clinically significant diuresis may impair milk production. the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for furosemide and any potential adverse effects on the breastfed infant from furosemide or from the underlying maternal condition. published reports indicate that premature infants with post conceptual age (gestational plus postnatal) less than 31 weeks receiving doses exceeding 1 mg/kg/24 hours may develop plasma levels which could be associated with potential toxic effects including ototoxicity [see warnings and precautions (5.3)] . furosemide in the first year of life, especially in patients born pre-term, may precipitate nephrocalcinosis/nephrolithiasis [see warnings and precautions (5.2)] . controlled clinical studies of furosemide did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. other reported clinical experience has not identified differences in responses between the elderly and younger patients. in general, dose selection for the elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy. this drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. because elderly patients are more likely to have decreased renal function, care should be taken in dose selection and it may be useful to monitor renal function [see clinical pharmacology (12.3)] .